DelveInsight’s “Chronic Obstructive Pulmonary Disease (COPD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Obstructive Pulmonary Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chronic Obstructive Pulmonary Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Obstructive Pulmonary Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Obstructive Pulmonary Disease (COPD): An Overview
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
In the United States, the term COPD includes two main conditions—emphysema and chronic bronchitis. In emphysema, the walls between many of the air sacs are damaged. As a result, the air sacs lose their shape and become floppy. This damage also can destroy the walls of the air sacs, leading to fewer and larger air sacs instead of many tiny ones. If this happens, the amount of gas exchange in the lungs is reduced.
Chronic and progressive dyspnea is the most characteristic symptom of COPD. Cough with sputum production is present in up to 30% of patients. These symptoms may vary from day to day and may precede the development of airflow limitation by many years.
COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. Spirometry is required to diagnose in this clinical context; the presence of a post-bronchodilator FEV1/FVC
Medical treatments of COPD include drugs, such as nicotine replacement therapy, beta-2 agonists and anticholinergic agents (bronchodilators), combined drugs using steroids and long-acting bronchodilators, mucolytic agents, oxygen therapy, and surgical procedures such as bullectomy, lung volume reduction surgery, and lung transplantation.
Chronic Obstructive Pulmonary Disease (COPD) Market Key Facts
The Chronic Obstructive Pulmonary Disease market in the United States was USD 9,379 million in the year 2020.
The United States accounts for the largest Chronic Obstructive Pulmonary Disease market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Among the EU5 countries, Germany had the highest Chronic Obstructive Pulmonary Disease market size, while the UK had the lowest market size for COPD.
The Chronic Obstructive Pulmonary Disease market in Japan was USD 361 million in the year 2020.
The diagnosed prevalent cases of COPD in the 7MM was 34,640,030 in 2020. These cases are expected to increase throughout the forecast period.
The estimates suggest a higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020.
In 2020, a lower number of males were affected by this contributing 6,588,516 total diagnosed prevalent population of COPD in the United States. In comparison, there were 10,867,088 females affected by COPD in 2020, in the US.
In the US, the highest cases were reported in the age group of 55–64 years i.e. 4,601,558, in 2020.
Among the five major European countries, Germany has the highest diagnosed prevalent population, followed by Italy and France. On the other hand, Spain had the lowest diagnosed prevalent population.
Among all the Chronic Obstructive Pulmonary Disease pipeline therapies, Itepekimab, Dupilumab, Benralizumab, and Mepolizumab, are the only biologics that are expected to target the eosinophilic inflammation pool of COPD, and hence are going to face competition which each other.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Obstructive Pulmonary Disease pipeline therapies. It also thoroughly assesses the Chronic Obstructive Pulmonary Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Chronic Obstructive Pulmonary Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chronic Obstructive Pulmonary Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Obstructive Pulmonary Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chronic Obstructive Pulmonary Disease Epidemiology, Segmented as –
Total diagnosed prevalent cases of COPD
Gender-specific diagnosed prevalent cases of COPD
Age-specific diagnosed prevalent cases of COPD
Diagnosed prevalent cases of COPD based on the severity of airflow limitation
Diagnosed prevalent cases of COPD based on symptoms and exacerbation history
Chronic Obstructive Pulmonary Disease (COPD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Obstructive Pulmonary Disease market or expected to be launched during the study period. The analysis covers the Chronic Obstructive Pulmonary Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Obstructive Pulmonary Disease drugs based on their sale and market share.
The report also covers the Chronic Obstructive Pulmonary Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Obstructive Pulmonary Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chronic Obstructive Pulmonary Disease Market Will Evolve and Grow by 2032 @
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Analysis
Many people with COPD have mild forms of the disease for which little therapy is needed other than smoking cessation. Even for more advanced stages of the disease, effective therapy is available that can control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life.
The goal of treating COPD is to help the person breathe easier and get back to regular activities; many treatments and lifestyle approaches can help. The patient may also try some natural and alternative treatment options. COPD treatment focuses on relieving symptoms, such as coughing, and breathing problems, and avoiding respiratory infections. The treatments are often based on the stages of COPD. There are certain lifestyle changes required to prevent COPD. Quitting smoking is an essential step in any treatment plan for COPD. Stopping smoking can keep COPD from getting worse and reducing the ability to breathe.
Pharmacotherapy for COPD consists of maintenance and reliever medications. Maintenance medications included inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), fixed-dose combination ICS+LABA, tiotropium (TIO), and inhaled ipratropium or fixed-dose combination ipratropium+albuterol (collectively referred to as ipratropium [IPR]).
Several major pharma and biotech companies are developing therapies for Chronic Obstructive Pulmonary Disease. Currently, AstraZeneca is leading the therapetics market with its Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage of clinical development. The potential drugs that can mark a significant change in the upcoming forecast period include Itepekimab, Ensifentrine, Dupilumab, Benralizumab, Mepolizumab, CHF6001/Tanimilast, and Acumapimod (BCT-197).
Chronic Obstructive Pulmonary Disease (COPD) Companies Actively Working in the Therapeutics Market Include
And Many More
Emerging and Marketed Chronic Obstructive Pulmonary Disease Therapies Covered in the Report Include:
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease Competitive Intelligence Analysis
4. Chronic Obstructive Pulmonary Disease Market Overview at a Glance
5. Chronic Obstructive Pulmonary Disease Disease Background and Overview
6. Chronic Obstructive Pulmonary Disease Patient Journey
7. Chronic Obstructive Pulmonary Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chronic Obstructive Pulmonary Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Obstructive Pulmonary Disease Unmet Needs
10. Key Endpoints of Chronic Obstructive Pulmonary Disease Treatment
11. Chronic Obstructive Pulmonary Disease Marketed Therapies
12. Chronic Obstructive Pulmonary Disease Emerging Drugs and Latest Therapeutic Advances
13. Chronic Obstructive Pulmonary Disease Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Obstructive Pulmonary Disease Market Outlook (In US, EU5, and Japan)
16. Chronic Obstructive Pulmonary Disease Companies Active in the Market
17. Chronic Obstructive Pulmonary Disease Access and Reimbursement Overview
18. KOL Views on the Chronic Obstructive Pulmonary Disease Market
19. Chronic Obstructive Pulmonary Disease Market Drivers
20. Chronic Obstructive Pulmonary Disease Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hyperphosphatemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hyperphosphatemia market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States